OBJECTIVES: Ministry of Health of Russian Federation announced the support of innovative development of pharmaceutical industry. In accordance with these plans, we aimed to develop a methodology for quantitative assessment of therapeutic value of innovative medical technologies in a multi-criteria decision analysis manner. METHODS: The questionnaire was developed during pilot survey (10 experts). Then 248 respondents assessed criteria significance (weights) of 14 features of an innovative drug and 7 features of а relevant disease. Also they estimated scale’s values. The respondents were medical practitioners and decision makers in healthcare. Results of the survey were analyzed using statistical methods.  RESULTS: The most valuable features are clinical efficacy and clinical safety with the weights of 9.77% and 9.08%, respectively. Absence of effective treatment of the disease, mortality and influence on quality of life also are among the valuable features with the weights of 8.08%, 7.72% and 7.47%, respectively. Minimal weights have new manufacturing technique of the drug (0.69%) and new drug formulation (0.03%). CONCLUSIONS: Significant and non-significant features of an innovative medical technology and disease for which it is intended in terms of therapeutic value were identified. We plan to optimize set of criteria and scales and then to assess reliability and validity of the developed instrument. This methodology being incorporated in the system of evaluation of medical technologies and combined with other methods of analyses will help decision-making regarding innovative drugs in Russia become more harmonious and transparent.